Other languages BioArctic AB

Equities

BIOA B

SE0010323311

Market Closed - Nasdaq Stockholm Other stock markets 11:29:53 2024-05-06 am EDT			5-day change	1st Jan Change
193.4 ^SEK	-0.10%		-2.08%	-27.78%

Apr. 22	Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	DJ
Apr. 20	BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	Apr. 20
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11
BioArctic AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14
BioArctic AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	Jan. 11
The European Medicines Agency's Scientific Advisory Group to Discuss the Marketing Authorisation Application for lecanemab	Jan. 11
BioArctic's Partner Obtains Marketing Authorization for Leqembi in China	Jan. 09
Leqembi® Approves for the Treatment of Alzheimer's Disease in China	Jan. 09
BioArctic, Eisai Sets Launch Date for Alzheimer’s Disease Drug in Japan	Dec. 13
BioArctic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08
Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi	23-10-25
BioArctic AB's Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI	23-10-25
Actualización de las fuertes variaciones del día: El lujo, ALD, Aperam, SBB, Entain, Bioarctic y otras	23-09-25
Les actions en mouvement : le luxe, ALD, Aperam, et d'autres	23-09-25
Japan Approves BioArctic's Treatment to Slow Effects of Alzheimer's Disease	23-09-25
BioArctic Wins Patent For Parkinson's Treatment in Japan	23-08-23
BioArctic AB Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease	23-08-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioArctic AB

Equities

BIOA B

SE0010323311

Other languages

Filters